USANA Health Sciences Inc (USNA)

From the record

USANA Health Sciences Inc's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

USANA Health Sciences Inc's 8 filed years say what it did: revenue went from $1.2 billion in fiscal 2018 to $925 million in fiscal 2026, down 3.5% a year; it rose in 3 of 7 years; the deepest fall was 28% from fiscal 2018 to fiscal 2024; net income was positive in 8 of 8 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2026-01-03, USANA Health Sciences Inc's diluted share count shrank about 1.3% a year, and dividends and buybacks returned about 32% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 17 sales and 0 purchases of their own stock on the open market in the year to 2026-10-23 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2026-01-03, USANA Health Sciences Inc earned about 2 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 98 cents per dollar of everything the company owns. Leverage: it owed about 28 cents per dollar of assets, and net share issuance: its share count shrank 3.1% over the year (the filed statements).

From the record

USANA Health Sciences Inc's standing among 18 graded names in its industry family: revenue of $925 million in fiscal 2026 ranks in the top 11% by size; a net margin of 1.2% ranks in the top 19%; revenue growth of -2.5% a year over the last 3 filed years ranks in the bottom 31% (its annual reports).

From the record

USANA Health Sciences Inc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Guest, Kevin (CEO & EXEC. CHAIRMAN OF BOARD, as filed), filing under that title since 2026-02-10, 9 months (bottom 15% of its family); the 17 officers and directors filing in the last fifteen months have been on the record a median of 9.7 years (top 23%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (top 12%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

USANA Health Sciences Inc's room to grow, from the newest filed statements (fiscal 2026): cash of $158 million against no long-term debt tagged leaves 21.3% of its assets as net cash, top 29% of its family; cash from operations less capital spending is 0.9% of revenue (top 42%); a gross margin of 78.3% (top 3%); research spending of 1.2% of revenue (top 50%) (its annual report).

From the record

USANA Health Sciences Inc's growth drivers, from the filed years to fiscal 2026: revenue grew -2.5% a year over the last three filed years against -3.5% over all 8, speeding up (top 8% of its family); the newest year grew 8.1% (top 42%); research spending grew -2.6% a year (top 37%); capital spending grew 9.9% a year (top 32%) (its annual reports). USANA Health Sciences Inc reported 3 lines of business in fiscal 2025: Core Nutritional at $775 million, Hiya at $132 million, All Other at $18 million. 2 of 3 grew in the latest filed year, and the largest line is 84% of revenue (its annual report).

From the record

USANA Health Sciences Inc's newest year against its own record: revenue of $925 million in fiscal 2026 came in 17.1% above the $790 million its prior three years' pace pointed to (top 19% of its family); net income of $11 million against a prior three-year average of $58 million (bottom 25%); a net margin of 1.2% against 6.3% before (bottom 36%) (its annual reports).